Resource competition may lead to effective treatment of antibiotic resistant infections

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Gomes, Antonio L C ^a   Galagan, James E ^a,b,c   Segrè, Daniel ^a,b,d  

^a BOSTON UNIVERSITY   (United States)

^b Boston University   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG DOSE REGIMEN; MATHEMATICAL MODEL; PLASMID;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 84892660249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080775     Document Type: Article

References (76)

1. Snitkin ES, Zelazny AM, Montero CI, Stock F, Mijares L, et al. (2011) Genome-wide recombination drives diversification of epidemic strains of Acinetobacter baumannii. Proc Natl Acad Sci U S A 108: 13758-13763.
2. Gubareva L (2004) Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus research 103: 199-203.
3. Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical microbiology reviews 12: 501-517.
4. Welch T, Fricke F, McDermott P, White D, Rosso M-L, et al. (2007) Multiple Antimicrobial Resistance in Plague: An Emerging Public Health Risk. PLoS ONE 2: e309.
5. Klokouzas A, Shahi S, Hladky S, Barrand M, van Veen H (2003) ABC transporters and drug resistance in parasitic protozoa. International journal of antimicrobial agents 22: 301-317.
6. Klevens M, Morrison M, Nadle J, Petit S, Gershman K, et al. (2007) Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States. JAMA: The Journal of the American Medical Association 298: 1763-1771.
7. Control ECfDPa. Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial Resistance Surveillance Network (EARSNet); 2010; Stockholm. ECDC.
8. Dagan R, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, et al. (2008) Seasonality of antibiotic-resistant Streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? The Journal of infectious diseases 197: 1094-1102.
9. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, et al. (1997) The population genetics of antibiotic resistance. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 24 Suppl 1: S9-16.
10. Rieux V, Carbon C, Azoulay-Dupuis E (2001) Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae. The Journal of infectious diseases 184: 66-72.
11. Rozen DE, McGee L, Levin BR, Klugman KP (2007) Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy 51: 412-416.
12. Quale J, Landman D, Saurina G, Atwood E, DiTore V, et al. (1996) Manipulation of a Hospital Antimicrobial Formulary to Control an Outbreak of Vancomycin-Resistant Enterococci. Clinical Infectious Diseases 23: 1020-1025.
13. Brown E, Nathwani D (2005) Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. Journal of Antimicrobial Chemotherapy 55: 6-9.
14. Masterton R (2005) Antibiotic cycling: more than it might seem? Journal of Antimicrobial Chemotherapy 55: 1-5.
15. Bonten M, Weinstein R (2006) Antibiotic cycling in intensive care units: the value of organized chaos? Critical care medicine 34: 549-551.
16. Francetić I, Kalenić S, Huić M, Mercep I, Makar-Ausperger K, et al. (2008) Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study. Croatian medical journal 49: 207-214.
17. Kollef M (2006) Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit? Clinical Infectious Diseases 43: S82-S88.
18. Hedrick T, Schulman A, McElearney S, Smith R, Swenson B, et al. (2008) Outbreak of resistant Pseudomonas aeruginosa infections during a quarterly cycling antibiotic regimen. Surgical infections 9: 139-152.
19. Martínez J-A, Nicolás J-M, Marco F, Horcajada J-P, Garcia-Segarra G, et al. (2006) Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Critical care medicine 34: 329-336.
20. Martinez J (2007) Advantages and drawbacks of antibiotic cycling in the critical care setting. Antibiotiques 9: 25-33.
21. Cadena J, Taboada CA, Burgess DS, Ma JZ, Lewis JS, et al. (2007) Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit. Bone marrow transplantation 40: 151-155.
22. Yeh P, Kishony R (2007) Networks from drug-drug surfaces. Molecular systems biology 3.
23. Bliss CI (1939) The toxicity of poisons applied jointly. Annals of Applied Biology 26: 585-615.
24. Ehrlich P (1913) Address in Pathology, ON CHEMIOTHERAPY: Delivered before the Seventeenth International Congress of Medicine. BMJ 2: 353-359.
25. Yeh P, Tschumi A, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nature Genetics 38: 489-494.
26. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A 105: 13977-13981.
27. Yeh P, Hegreness M, Aiden A, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460-466.
28. Ankomah P, Levin B (2012) Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum. PLoS pathogens 8: e1002487.
29. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacological reviews 47: 331-385.
30. Torella J, Chait R, Kishony R (2010) Optimal Drug Synergy in Antimicrobial Treatments. PLoS Comput Biol 6: e1000796.
31. Bollenbach T, Quan S, Chait R, Kishony R (2009) Nonoptimal Microbial Response to Antibiotics Underlies Suppressive Drug Interactions. Cell 139: 707-718.
32. Michel J-B, Yeh P, Chait R, Moellering R, Kishony R (2008) Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A 105: 14918-14923.
33. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446: 668-671.
34. Palmer A, Angelino E, Kishony R (2010) Chemical decay of an antibiotic inverts selection for resistance. Nature chemical biology 6: 105-107.
35. Cantón R, Coque T, Baquero F (2003) Multi-resistant Gram-negative bacilli: from epidemics to endemics. Current opinion in infectious diseases 16: 315-325.
36. Kollef M (2005) Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. Critical care (London, England) 9: 459-464.
37. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
38. Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature reviews Microbiology 5: 939-951.
39. Bergstrom C, Lo M, Lipsitch M (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 101: 13285-13290.
40. Bonhoeffer S, Lipsitch M, Levin B (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94: 12106-12111.
41. Kouyos R, Abel zur Wiesch P, Bonhoeffer S (2011) Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards. PLoS Comput Biol 7: e1001094.
42. D'Agata E, Dupont-Rouzeyrol M, Magal P, Olivier D, Ruan S (2008) The Impact of Different Antibiotic Regimens on the Emergence of Antimicrobial- Resistant Bacteria. PLoS ONE 3: e4036.
43. Dall'Antonia M, Coen PG, Wilks M, Whiley A, Millar M (2005) Competition between methicillin-sensitive and -resistant Staphylococcus aureus in the anterior nares. The Journal of hospital infection 61: 62-67.
44. Lipsitch M, Dykes JK, Johnson SE, Ades EW, King J, et al. (2000) Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine 18: 2895-2901.
45. Smith VH, Holt RD (1996) Resource competition and within-host disease dynamics. Trends in ecology & evolution 11: 386-389.
46. Imran M, Smith H (2007) The Dynamics of Bacterial Infection, Innate Immune Response, and Antibiotic Treatment. Discrete and Continuous Dynamical Systems - B 8: 127-143.
47. Tenover FC (2006) Mechanisms of antimicrobial resistance in bacteria. The American journal of medicine 119: S3-10; discussion S62-70.
48. Diard M, Garcia V, Maier L, Remus-Emsermann MNP, Regoes RR, et al. (2013) Stabilization of cooperative virulence by the expression of an avirulent phenotype. Nature 494: 353-356.
49. Jiang J-R, Yen S-Y, Wang J-Y (2011) Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients. Respirology (Carlton, Vic) 16: 308-313.
50. Osman AS, Jennings FW, Holmes PH (1992) The rapid development of drug-resistance by Trypanosoma evansi in immunosuppressed mice. Acta Tropica 50: 249-257.
51. De Gelder L, Ponciano JM, Abdo Z, Joyce P, Forney LJ, et al. (2004) Combining mathematical models and statistical methods to understand and predict the dynamics of antibiotic-sensitive mutants in a population of resistant bacteria during experimental evolution. Genetics 168: 1131-1144.
52. Gill W, Harik N, Whiddon M, Liao R, Mittler J, et al. (2009) A replication clock for Mycobacterium tuberculosis. Nature medicine 15: 211-214.
53. Hegreness M, Shoresh N, Hartl D, Kishony R (2006) An Equivalence Principle for the Incorporation of Favorable Mutations in Asexual Populations. Science 311: 1615-1617.
54. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS pathogens 6: e1001042.
55. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010) Antibiotic resistance of bacterial biofilms. International journal of antimicrobial agents 35: 322-332.
56. Leung RS, Katial R (2008) The diagnosis and management of acute and chronic sinusitis. Primary care 35: 11-24, v-vi.
57. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, et al. (2007) The molecular evolution of methicillin-resistant Staphylococcus aureus. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 13: 222-235.
58. Mahillon J, Chandler M (1998) Insertion Sequences. Microbiol Mol Biol Rev 62: 725-774.
59. Recchia GD, Hall RM (1997) Origins of the mobile gene cassettes found in integrons. Trends in microbiology 5: 389-394.
60. Syvanen M (1984) The evolutionary implications of mobile genetic elements. Annual review of genetics 18: 271-293.
61. Frost LS, Leplae R, Summers AO, Toussaint A (2005) Mobile genetic elements: the agents of open source evolution. Nature reviews Microbiology 3: 722-732.
62. Sørensen SJ, Bailey M, Hansen LH, Kroer N, Wuertz S (2005) Studying plasmid horizontal transfer in situ: a critical review. Nature reviews Microbiology 3: 700-710.
63. Robicsek A, Jacoby Ga, Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. The Lancet infectious diseases 6: 629-640.
64. Naimi TS, Ledell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, et al. (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA : the journal of the American Medical Association 290: 2976-2984.
65. Colomer-Lluch M, Jofre J, Muniesa M (2011) Antibiotic resistance genes in the bacteriophage DNA fraction of environmental samples. PloS one 6: e17549.
66. Lindsay JA, Holden MTG (2006) Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Functional & integrative genomics 6: 186-201.
67. Rupp ME, Fey PD (2003) Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63: 353-365.
68. Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, Rosenstiel P, et al. (2013) When the Most Potent Combination of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown Transition. PLoS Biology 11: 13.
69. Beardmore R, Pena-Miller R (2010) Antibiotic cycling versus mixing: the difficulty of using mathematical models to definitively quantify their relative merits. Mathematical biosciences and engineering : MBE 7: 923-933.
70. Beardmore R, Peña-Miller R (2010) Rotating antibiotics selects optimally against antibiotic resistance, in theory. Mathematical biosciences and engineering : MBE 7: 527-552.
71. Bonhoeffer S, Wiesch PAZ, Kouyos R (2010) Rotating antibiotics does not minimize selection for resistance. Mathematical biosciences and engineering : MBE 7: 919-922.
72. Chow K, Wang X, Curtiss R, Castillo-Chavez C (2010) Evaluating the efficacy of antimicrobial cycling programmes and patient isolation on dual resistance in hospitals. Journal of Biological Dynamics 5: 27-43.
73. Enne VI, Livermore DM, Stephens P, Hall LM (2001) Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357: 1325-1328.
74. Gottesman BS, Carmeli Y, Shitrit P, Chowers M (2009) Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 49: 869-875.
75. zur Wiesch P, Kouyos R, Engelstädter J, Regoes R, Bonhoeffer S (2011) Population biological principles of drug-resistance evolution in infectious diseases. The Lancet Infectious Diseases 11: 236-247.
76. Chait R, Vetsigian K, Kishony R (2012) What counters antibiotic resistance in nature? Nature chemical biology 8: 2-5.